Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 5, 2026, 2:26 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 193–216 of 326 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: CAP-IT Clear all

Conditions: Hypertension, Medication Adherence
Interventions: Medication Reminder App; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Glioblastoma
Interventions: Temozolomide, Lomustine, Regorafenib, Radiation, Paxalisib, VAL-083, VT1021, Troriluzole, ADI-PEG 20, AZD1390, Tinostamustine; Drug · Radiation · Biological
Lead sponsor: Global Coalition for Adaptive Research; Other
Eligibility: 18 Years and older
Enrollment: 2,250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2030
U.S. locations: 42
States / cities: Birmingham, Alabama • La Jolla, California • Los Angeles, California + 31 more

Conditions: Cocaine Dependence
Interventions: Adderall-ER, Topiramate, Placebo; Drug · Other
Lead sponsor: New York State Psychiatric Institute; Other
Eligibility: 18 Years to 60 Years
Enrollment: 169 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 2
States / cities: New York, New York • Philadelphia, Pennsylvania

Conditions: Clostridium Difficile Infection, Hematologic Diseases, Bone Marrow Transplant, Oncologic Disorders
Interventions: Vancomycin Oral Capsule, Placebo Oral Capsule; Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 9 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: HER2 Amplified, Advanced Breast Cancer, Human Epidermal Growth Factor Receptor 2 (HER2)
Interventions: Enzalutamide, Trastuzumab; Drug
Lead sponsor: Astellas Pharma Global Development, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2024
U.S. locations: 16
States / cities: Anaheim, California • Los Angeles, California • San Francisco, California + 12 more

Conditions: Sleep Disorders
Interventions: Zolpidem, Escitalopram, Placebo; Drug
Lead sponsor: University of Pittsburgh; Other
Eligibility: 20 Years to 50 Years
Enrollment: 69 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2002 – 2008
U.S. locations: 1
States / cities: Pittsburgh, Pennsylvania

Conditions: COVID-19
Interventions: Nirmatrelvir, Ritonavir, Placebo for nirmatrelvir, Placebo for ritonavir; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 12 Years and older
Enrollment: 158 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2023
U.S. locations: 25
States / cities: San Francisco, California • Washington D.C., District of Columbia • Doral, Florida + 15 more

Conditions: Gastroesophageal Reflux Disease (GERD)
Interventions: Dexlansoprazole; Drug
Lead sponsor: Takeda; Industry
Eligibility: 2 Years to 11 Years
Enrollment: 71 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 6
States / cities: Mobile, Alabama • San Francisco, California • Atlanta, Georgia + 3 more

Conditions: Acute Coronary Syndrome
Interventions: Polypill; Combination Product
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 1,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 4
States / cities: Dallas, Texas

Conditions: Gastrointestinal Stromal Tumors
Interventions: RAD001, Imatinib 600mg/day (Glevec is the brand name for imatinib), Imatinib 800mg/day (Glevec is the brand name for imatinib); Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 117 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2008
U.S. locations: 3
States / cities: Boston, Massachusetts • New York, New York • Philadelphia, Pennsylvania

Conditions: Crohn's Disease
Interventions: TAK-279, Placebo; Drug
Lead sponsor: Takeda; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 268 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 30
States / cities: Murrieta, California • Orange, California • Clearwater, Florida + 27 more

Conditions: Olfactory Dysfunction, Smell Loss, Anosmia, Hyposmia
Interventions: Sudoku Puzzles, ScentCare (Olfactory Training Device); Other
Lead sponsor: Johns Hopkins University; Other
Eligibility: 60 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Hematoma, Subdural, Chronic
Interventions: Curcumin Pill, Placebo pills; Drug
Lead sponsor: University of New Mexico; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Albuquerque, New Mexico

Conditions: Colorectal Cancer
Interventions: SBIRT, Referral as Usual (RAU); Behavioral
Lead sponsor: Columbia University; Other
Eligibility: 45 Years and older
Enrollment: 880 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: Polycythemia Vera, Thrombocythemia
Interventions: CC-4047, Prednisone; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2018
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Aneurysmal Subarachnoid Hemorrhage (aSAH)
Interventions: GTX-104, Nimotop 30 MG Oral Capsule; Drug
Lead sponsor: Grace Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 22
States / cities: Birmingham, Alabama • Phoenix, Arizona • Fresno, California + 19 more

Conditions: Postural Tachycardia Syndrome
Interventions: Placebo, Modafinil, Propranolol; Drug
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2026
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Autism Spectrum Disorder
Interventions: Memantine, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 8 Years to 17 Years
Enrollment: 84 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2018
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Central Centrifugal Cicatricial Alopecia
Interventions: Revian Red All LED cap; Device
Lead sponsor: Wake Forest University Health Sciences; Other
Eligibility: 18 Years to 65 Years · Female only
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Winston-Salem, North Carolina

Conditions: Vasectomy, NSAIDs, Post-operative Care
Interventions: Acetaminophen, ibuprofen, oxycodone; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2035
U.S. locations: 2
States / cities: New York, New York • White Plains, New York

Conditions: Healthy, Body Mass Index, Normal, Postprandial Hyperglycemia
Interventions: Alpha galactosidase, Placebo; Dietary Supplement
Lead sponsor: Iowa State University; Other
Eligibility: 21 Years to 34 Years
Enrollment: 21 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2023
U.S. locations: 1
States / cities: Ames, Iowa

Conditions: Schizophrenia and Related Disorders, Mitochondrial Alteration, Cognitive Impairment
Interventions: MitoQ, Placebo; Drug
Lead sponsor: Mclean Hospital; Other
Eligibility: 18 Years to 35 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: New Haven, Connecticut • Belmont, Massachusetts

Conditions: Alzheimer Dementia
Interventions: Methylphenidate Extended Release Oral Capsule, Placebo; Drug · Other
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 55 Years to 95 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 1
States / cities: Charlestown, Massachusetts

Conditions: Osteoarthritis, Hip
Interventions: Periarticular injection (Deep injection), Periarticular injection (Superficial injection), Bupivacaine, Placebo; Procedure · Drug
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 50 Years to 75 Years
Enrollment: 180 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2019
U.S. locations: 1
States / cities: New York, New York

Search by objective public record fields.

Pill Bottle vs Reminder App

A Trial to Evaluate Multiple Regimens in Newly Diagnosed and Recurrent Glioblastoma

Multicenter Trial of Combined Pharmacotherapy to Treat Cocaine Dependence

Vancomycin for C Difficile NAAT+/EIA- Hematology Oncology Patients

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

Characteristics of Sleep Patterns in Young Adults With and Without Insomnia

A Study to Learn About the Study Medicines (Nirmatrelvir Plus Ritonavir) in People Aged 12 Years or Older With COVID-19 and a Compromised Immune System

A Study to Check the Safety of Dexlansoprazole and Learn if it Can Treat Symptomatic Nonerosive Gastroesophageal Reflux Disease in Children 2 to 11 Years Old

A Polypill for Acute Coronary Syndrome

Everolimus in Combination With Imatinib in Patients With Glivec Refractory/Resistant Gastrointestinal Stromal Tumors

A Study on the Safety of TAK-279 and Whether it Can Reduce Inflammation in the Bowel of Participants With Moderately to Severely Active Crohn's Disease

Scents of Progress: Leveraging a Novel Device for Olfactory Training in Older Adults

Curcumin/Turmeric as a Treatment for Patients With Subdural Hematomas Recurrence

Community Health Workers United to Reduce Colorectal Cancer and Cardiovascular Disease Among People at Higher Risk

Pomalidomide for Myelofibrosis Patients

Safety and Tolerability of GTX-104 Compared with Oral Nimodipine in Patients with ASAH

Modafinil and Cognitive Function in POTS

Behavioral and Neural Response to Memantine in Adolescents With Autism Spectrum Disorder

A Study of Revian Red All LED Cap as a Novel Treatment for Central Centrifugal Cicatricial Alopecia

Post-Vasectomy Pain Study

Glycemic Response of Whole Beans and Bean Products

MitoQ for Early-phase Schizophrenia-spectrum Disorder and Mitochondrial Dysfunction

A Pilot of Methylphenidate in Mild Cognitive Impairment and Dementia Participants.

Minimal Opioid Use After Total Hip Replacement (THR)